ArticleOncogene2011
Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation.
Article in Oncogene, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Prognostic significance of miR-378 in cancers: a meta-analysis.BMC cancer · 2025Pooled it
- Association of MiRNA Polymorphisms Involved in the PI3K/ATK/GSK3β Pathway with T2DM in a Chinese Population.Pharmacogenomics and personalized medicine · 2025Article
- Functional analysis of a putative HER2-associated expressed enhancer, Her2-Enhancer1, in breast cancer cells.Scientific reports · 2023Article
- miR-378a-3p promotes renal cell carcinoma proliferation, migration, and invasion by targeting TOB2.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- MicroRNA miR-378-3p is a novel regulator of endothelial autophagy and function.Journal of molecular and cellular cardiology plus · 2023Article
- The microRNA Lifecycle in Health and Cancer.Cancers · 2022Review
- Processing body (P-body) and its mediators in cancer.Molecular and cellular biochemistry · 2022Review
- Hub microRNAs and genes in the development of atrial fibrillation identified by weighted gene co-expression network analysis.BMC medical genomics · 2021Article
- miR-378-3p Knockdown Recapitulates Many of the Features of Myelodysplastic Syndromes.The American journal of pathology · 2021Article
- MicroRNA-378a-3p is overexpressed in psoriasis and modulates cell cycle arrest in keratinocytes via targeting BMP2 gene.Scientific reports · 2021Article
- The Role of Noncoding RNAs in the Regulation of Anoikis and Anchorage-Independent Growth in Cancer.International journal of molecular sciences · 2021Review
- Article
- microRNA-378a-5p iS a novel positive regulator of melanoma progression.Oncogenesis · 2020Article
- Intricate crosstalk between MYC and non-coding RNAs regulates hallmarks of cancer.Molecular oncology · 2019Review
- Analysis of association of potentially functional genetic variants within genes encoding miR-34b/c, miR-378 and miR-143/145 with prostate cancer in Serbian population.EXCLI journal · 2019Article
- EPA significantly improves anti-EGFR targeted therapy by regulating miR-378 expression in colorectal cancer.Oncology letters · 2018Article
- Long non-coding RNA OIP5-AS1 promotes proliferation of lung cancer cells and leads to poor prognosis by targeting miR-378a-3p.Thoracic cancer · 2018Article
- MicroRNA-378 enhances migration and invasion in cervical cancer by directly targeting autophagy-related protein 12.Molecular medicine reports · 2018Article
- MicroRNA-378 protects against intestinal ischemia/reperfusion injury via a mechanism involving the inhibition of intestinal mucosal cell apoptosis.Cell death & disease · 2017Article
- Podocytes regulate the glomerular basement membrane protein nephronectin by means of miR-378a-3p in glomerular diseases.Kidney international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The c-Myc transcription factor activates a cascade of downstream targets to form a complex transcriptional program that ultimately leads to cellular transformation. Although a large number of protein-encoding genes as well as non-coding RNAs were identified as Myc targets, only a few have been validated to be functionally important for c-Myc-driven transformation. Here, we identify a microRNA (miRNA), miR-378, as a novel target of the c-Myc oncoprotein that is able to cooperate with activated Ras or HER2 to promote cellular transformation. Mechanistically, miR-378 achieves this oncogenic effect, at least in part, by targeting and inhibiting the anti-proliferative BTG family member, TOB2, which is further elucidated as a candidate tumor suppressor to transcriptionally repress proto-oncogene cyclin D1. Therefore, our study identifies miR-378-TOB2-cyclin D1 as a functional module to mediate the cross talk between Myc and Ras signaling in cellular transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.